Table 1 Pooled pCR outcome of NAC-treated Asian breast cancer patients according to molecular subtypes, biomarkers and genetic variations

Molecular subtypes

OR

95%CI

Overall P-value

Favoured outcome

Taxane-Anthracycline

Luminal-like vs HER2E

4.08

2.78,6.00

P< 0.00001

HER2E

Luminal A vs HER2E

5.27

1.16, 23.86

P=0.03

HER2E

Luminal B vs HER2E

2.78

1.42,5.44

P=0.0003

HER2E

Luminal, combined vs HER2E

3.89

2.69,5.64

P< 0.00001

HER2E

TNBC vs Luminal-like

4.45

2.79,7.11

P< 0.0001

TNBC

TNBC vs Luminal A

11.66

3.64, 37.38

P< 0.00001

TNBC

TNBC vs Luminal B

3.89

2.20, 6.87

P< 0.00001

TNBC

TNBC vs Luminal, combined

4.59

3.35, 6.29

P< 0.00001

TNBC

Taxane-platinum

Luminal-like vs HER2E (the subgroup-assessed outcome)

2.30

1.66,319

P< 0.00001

HER2E

Luminal A vs HER2E

12.11

4.41,33.26

P< 0.00001

HER2E

Luminal B vs HER2E

5.92

2.59,13.54

P< 0.0001

HER2E

Luminal, combined vs HER2E

3.37

1.66, 6.84

P= 0.0008

HER2E

Luminal, combined vs HER2E (subgroup- assessed outcome)

3.80

2.02,7.13

P< 0.0001

HER2E

Luminal B vs Luminal A

3.26

1.14, 9.26

P=0.03

Luminal B

TNBC vs Luminal A

7.14

2.82,18.04

P< 0.0001

TNBC

TNBC vs Luminal B

2.19

1.09,4.41

P=0.03

TNBC

TNBC vs Luminal-like

3.79

1.94, 7.40

P< 0.0001

TNBC

Anthracycline-based

Biomarkers

ER− vs ER+

1.95

0.98,3.89

P=0.06

ER−

ER− vs ER+ (subgroup-population)

2.52

1.43, 4.44

P=0.001

ER−

PR− vs PR+

2.40

1.52, 3.80

P=0.0002

PR−

HER2− vs HER2+

2.31

1.42,3.75

P=0.0008

HER2−

Taxane-based

HR− vs HR+

1.96

1.24, 3.08

P=0.004

HR−

Taxane-anthracycline

ER− vs ER+

3.19

2.15, 4.75

P< 0.00001

ER−

PR− vs PR+

3.11

2.12, 4.56

P< 0.00001

PR−

HR− vs HR+

2.38

0.87,6.53

P=0.09

HR−

HR− vs HR+ (Subgroup-population)

3.58

1.62,7.90

P=0.002

HR−

HER2− vs HER2+

1.78

1.05,3.02

P=0.0008

HER2+

nm23-H1− vs nm23-H1+

6.74

2.13,21.30

P=0.001

nm23-H1−

CK5/6− vs CK5/6+

1.87

1.03,3.39

P=0.04

CK5/6−

High Ki67 vs low Ki67

2.98

1.79,4.97

P< 0.0001

high Ki67

High Ki67 vs low Ki67

(subgroup- 14% cut-off)

1.82

0.65,5.10

P=0.20

high Ki67

High Ki67 vs low Ki67 (subgroup- 14% cut-off, primary objective)

3.12

1.93,5.04

P< 0.00001

high Ki67

High Ki67 vs low Ki67

(Subgroup- 20% cut-off)

2.88

1.36,6.10

P=0.006

high Ki67

Taxane-platinum

ER− vs ER+

4.91

3.20,7.53

P< 0.00001

ER−

PR− vs PR+

3.82

2.45,5.90

P< 0.00001

PR−

HR− vs HR+

2.71

1.43,5.41

P< 0.00001

HR−

High Ki67 vs low Ki67

2.20

0.74,6.59

P=0.16

high Ki67

High Ki67 vs low Ki67

(Subgroup- 20% cut-off)

4.37

1.62,11.75

P=0.003

high Ki67

HER2− vs HER2+

2.44

0.84,7.06

P< 0.0001

HER2+

HER2− vs HER2+ (Subgroup-influential)

4.14

2.51,6.85

P< 0.00001

HER2+

TP vs TA

In HER2+ breast cancer

1.60

0.66,3.88

P=0.30

TP

Subgroup- HER2+ breast cancer study

2.36

1.07,5.26

P=0.03

TP

Taxane-anthracycline

Genetic variation

PIK3CA wildtype vs PIK3CA mutated

2.44

1.42,4.19

P=0.001

PIK3CA wildtype